ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,253,000 | -2.7% | 10,674 | +11.5% | 0.02% | -4.3% |
| Q4 2021 | $1,288,000 | -14.8% | 9,576 | +0.9% | 0.02% | -14.8% |
| Q3 2021 | $1,512,000 | +13.2% | 9,488 | -6.6% | 0.03% | +3.8% |
| Q2 2021 | $1,336,000 | +12.6% | 10,159 | +10.3% | 0.03% | 0.0% |
| Q1 2021 | $1,187,000 | +4.0% | 9,212 | +34.7% | 0.03% | -7.1% |
| Q4 2020 | $1,141,000 | +189.6% | 6,841 | +95.6% | 0.03% | -6.7% |
| Q1 2020 | $394,000 | -46.7% | 3,497 | -34.1% | 0.03% | +50.0% |
| Q4 2019 | $739,000 | +45.2% | 5,309 | +18.9% | 0.02% | +5.3% |
| Q2 2019 | $509,000 | +6.7% | 4,466 | +10.3% | 0.02% | -5.0% |
| Q1 2019 | $477,000 | +61.1% | 4,049 | -14.3% | 0.02% | +53.8% |
| Q4 2018 | $296,000 | -13.7% | 4,722 | -2.4% | 0.01% | -7.1% |
| Q3 2018 | $343,000 | +3.9% | 4,839 | -2.6% | 0.01% | -6.7% |
| Q2 2018 | $330,000 | +55.7% | 4,967 | +53.5% | 0.02% | +50.0% |
| Q1 2018 | $212,000 | – | 3,236 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |